• It's Here!

    Etf Pro

    Get the big financial market moves right, bullish or bearish with Hedgeye’s ETF Pro.

  • It's Here


    Identify global risks and opportunities with essential macro intel using Hedgeye’s Market Edges.

Click image to enlarge.

This One Picture Captures Everything Wrong With Wall Street | $VRX - VRX consensus

Source: Bloomberg

Valeant Pharmaceuticals (VRX) is trading around $80, down almost 70% from its August high. Here's the current breakdown of the 25 Wall Street analysts covering the stock:

  • 65% currently rate VRX a Buy
  • The average analyst price target is $199
  • That implies approximately 150% upside

No words.

Reality check. Our Healthcare analysts just released a research note to institutional subscribers outlining why we think shares are worth $20. To be clear, we’ve long been skeptical.

CLICK HERE to read their original Short thesis on VRX from 7/22/14.